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Survivin, a unique member of the inhibitor of apoptosis (IAP) protein family, is highly expressed in cancer but is undetectable in
nonproliferating normal adult tissues, suggesting a potential role in tumorigenesis. Differential splicing of survivin pre-mRNA results in
three new survivin variants, survivin-DEx3, survivin-2B, and survivin-3B. Loss of survivin-2B expression was found in the later stage of
cancer development, while survivin and survivin-DEx3 are not, suggesting a differential role of them in tumour development. In this
minireview, the author intends to summarise and discuss the current data relevant to the role of survivin and its splicing variants in
tumorigenesis, which may facilitate further investigation in this interesting area.
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Abnormal inhibition of physiological apoptosis during homeostasis
is thought to be a critical step for carcinogenesis or tumorigenesis,
although the underlying mechanism is not fully understood. In
addition to the Bcl-2 protein family, which includes both
antiapoptotic and proapoptotic factors, the inhibitor of apoptosis
(IAP), a relative new protein family, is mainly involved in
antiapoptosis. This family of proteins are characterised by a
signature domain of about 70 amino acids (aa) termed baculovirus
IAP repeat (BIR), which is evolutionarily conserved including virus,
yeast, nematode, fly, and mammalian. Survivin, a unique member
in the IAP family, is undetectable in most normal adult tissues but
is highly expressed in cancer. Survivin is cell cycle regulated, and
involved in both control of programmed cell death (apoptosis) and
regulation of cell division. The molecular mechanism by which
survivin counters against apoptosis and facilitates cell division has
been extensively explored in cancer cells (Li, 2003). More effort
appears to be required for the delineation of the role of survivin in
tumorigenesis at the molecular level. Development of new model
systems may be desired to unravel the mechanism for the function
of survivin and its variants in tumorigenesis. Nevertheless, there is
ample data indicating that survivin and its variants may have a
differential role in tumorigenesis and cancer development. This
minireview will summarise the data as a collective reference, with
the intent to indicate where the current research has brought us and
to help in the elucidation of future research directions in this
interesting area.
SURVIVIN IN TUMORIGENESIS
The initial indication for survivin to be involved in carcinogenesis
is the observation that survivin is highly expressed in cancer as
well as during development, but it is undetectable in nonprolifer-
ating adult tissues. Later studies indicated that survivin expression
also occurs in very early stages of cancer, and there is a direct
correlation of survivin expression with the stage of cancer and
other malignant parameters. Selected studies with emphasis on
tumorigenesis are discussed below.
Role of survivin in colorectal tumorigenesis
Kawasaki et al (1998) reported that survivin expression reduced
apoptotic index in both bcl-2-positive and -negative colorectal
carcinomas, and patients with low apoptotic index in their
tumours had significantly worse survival rates. This observation
suggests that survivin is an independent prognostic factor.
Consistently, immunohistochemical analysis of 52 colorectal
carcinoma samples indicated that apoptotic index is significantly
lower but PCNA labelling index is significantly higher in the 27
survivin-positive cases than in the 25 survivin-negative cases
(Chen et al, 2004). This suggests that survivin expression not only
inhibits apoptosis but it also is associated with cell proliferation.
Reports from Kawasaki et al (2001) and Lin et al (2003) further
explored the role of survivin in colorectal carcinogenesis.
Immunohistochemical analysis of 143 hyperplastic polyps, 171
adenomas with low dysplasia, 42 adenomas with high dysplasia,
and 60 carcinomas indicated that the immunoreactivity of survivin
(but not bcl-2) significantly increases in the transition from
adenoma with low dysplasia to high dysplasia/carcinoma. This
transition is significantly associated with a decrease of apoptotic
index, and an increase of Ki-67 labelling index and microvessel
density (Kawasaki et al, 2001). Lin et al (2003) showed that the
positivity of survivin significantly increased in the transition from
normal mucosas (0.0%) to adenomas with low-grade dysplasia
(31.7%) to high-grade dysplasia (56.7%) or carcinomas (63.2%)
although survivin expression was not associated with the
histological differentiation grade of colorectal carcinoma. To-
gether, these results indicate an important role of survivin in
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study of signalling pathways relevant to colorectal tumorigenesis
in other reports (see below).
Using HT-29 cell lines with inducible wild-type APC or
dominant-negative TCF-4, Zhang et al (2001) showed that wt-
APC downregulates survivin expression via suppressing b-catenin/
TCF-4 signalling. In addition, survivin expression is preferentially
in the lower crypt and inversely correlates with the expression level
of wild-type APC. Consistent with the finding from Zhang et al,
Kim et al (2003) reported that b-catenin/TCF signalling in HCT116
cells increases survivin promoter activity about 6–12-folds in
comparison with that in HeLa cells lacking such signalling.
Mutagenesis of the two proximal TCF-binding elements abolished
survivin promoter activity by 75–79%. Survivin expression is
strong in embryonic intestinal crypts, but lost in TCF-4 knockout
intestinal crypts (Kim et al, 2003). Expression of nondestructible
b-catenin mutants increases survivin expression and protected
against UV-B-induced apoptosis (Kim et al, 2003). Treatment of
HT-29 colon carcinoma cells with the chemopreventive drug
sulindac induces b-catenin degradation and decreases the expres-
sion of survivin but not Bcl-2 (Zhang et al, 2004b).
On the basis of these findings, one mechanism for colorectal
tumorigenesis appears to be that APC gene mutation results in
upregulation of survivin transcription through activation of
b-catenin/TCF-4 signalling. Survivin upregulation increases apop-
tosis inhibition and cell survival/overgrowth, and initiates
tumorigenesis. However, in normal colorectal intestinal crypts,
wild-type APC signalling suppresses survivin transcription
through inactivation of b-catenin/TCF-4 signalling. This
will increase apoptosis from crypt bottom to top, decrease cell
population and block tumorigenesis. Interestingly, it was recently
reported that inhibition of Wnt-2 signalling, by either a novel
monoclonal antibody against human Wnt-2 ligand or Wnt-2 small
interfering RNA, downregulates b-catenin and survivin, and
induces apoptosis in Wnt-2-overexpressing human melanoma
(You et al, 2004a) and non-small-cell lung cancer cells (You et al,
2004b), but not in normal cells lacking Wnt-2 expression. In
addition, it was also reported that proteasome inhibitor, MG132-
induced apoptosis is associated with fragmentation of b-catenin,
reduction of TCF transcriptional activity and downregulation of
survivin in hepatocellular carcinoma cells (Cervello et al, 2004).
These findings suggest that the b-catenin/TCF-4/survivin pathway
may not only be responsible for colorectal tumorigenesis but it
may also possibly be responsible for tumorigenesis in other types
of cancer.
Role of survivin in virus infection-induced carcinogenesis
The clue for survivin involvement of virus-induced tumorigenesis
comes from the observation that expression of survivin transcript
was found in all the nine human T-cell leukaemia virus type I
(HTLV-I)-positive T-cell lines examined and downregulation of
survivin by antisense oligonucleotides inhibited growth in the
HTLV-I-infected MT-1 T-cell line (Mori et al, 2001). Consistently,
resveratrol, a chemopreventive agent commonly found in human
diet, downregulates survivin expression and induces growth
inhibition and apoptosis in HTLV-1-infected cell lines (Hayashi-
bara et al, 2002). In addition, high survivin expression was
detected in primary cells of patients with acute adult T-cell
leukaemia (ATL), but not in the cells of patients with chronic ATL
or normal peripheral blood mononuclear cells (Mori et al, 2001). It
will be interesting to know whether this is associated with a
difference of HTLV infection in these two types of ATL.
Immunohistochemical analysis of 73 cervical squamous tissues
for survivin expression, including 31 normal, 17 low- and 15 high-
grade squamous intraepithelial lesions (LSIL, HSIL), and
10 squamous cell carcinomas (SCC) from cone biopsy
and hysterectomy specimens, indicated that although nuclear
staining of survivin was detected in normal mucosa, LSIL, and
HSIL, survivin expression is highest in human papillomavirus
(HPV)-infected tissue samples. Moreover, in situ hybridisation
of serial sections showed the colocalisation of HPV and survivin
(Frost et al, 2002). This report indicated that the histologic
correlation between nuclear staining of survivin and HPV infection
suggests involvement of survivin in HPV-mediated disruption
of normal cellular maturation (Frost et al, 2002). However,
alternative roles of survivin upregulation in HPV-infected
cells may exist (see below). In another report, immunohistochem-
ical analysis for survivin expression and nested PCR plus direct
sequencing for detection of HPV presence showed that survivin
expression was evident in 57.1% (four out of seven) HPV
þ
(high level) and 100% (four out of four) HPV
  (low level) oral
SCC, and 85.7% (six out of seven) HPV
þ and 55.5% (five out
of nine) HPV
  oral leucoplakias, and 0% (zero out of 20) control
oral mucosa samples, and that survivin expression was found
to be greater in HPV
þ precancerous lesions than in HPV
  ones
(Lo Muzio et al, 2004). Since HPV has been thought to be involved
in the development of several oral diseases, such as premalignant
mucosal lesions and oral carcinoma, these authors suggested that
survivin may directly or indirectly be regulated by HPV and may
be involved in HPV-induced deregulation during maturation of
squamous epithelium through modulation of the apoptotic
processes (Lo Muzio et al, 2004). Consistent with the possibility
that HPV may induce survivin expression, cDNA microarray
indicated that HPV E6/E7 upregulates survivin (Nees et al, 2000).
However, Veress et al found the HPV E6 protein can transcrip-
tionally upregulate survivin promoter activity over 10-folds in
HeLa cells in comparison with empty vector control, while HPV E7
alone has no effect on survivin transcription (personal commu-
nication, University of Debrecen, Hungary). An interesting
question is whether upregulation of survivin after virus infection
is a universal phenomenon. Zhao et al reported that adenovirus
type-2 also upregulates survivin in HeLa cells after infection
(Zhao et al, 2003). An RNA probe derived from the adenovirus
type 2-infected HeLa cells was used to examine cDNA microarrays
of 12309 unique genes. The results showed that survivin is
one of the top 53 genes with significant changes (35 up and
18 down) and significantly upregulated (Zhao et al, 2003).
Consistent with this finding, Punga and Akusjarvi (2003) showed
that the adenovirus 2 E1B-55K protein upregulates survivin by
binding to and blocking p53 as a transcriptional repressor on
survivin promoter.
The notion that upregulation of survivin during virus infection
may have a role in facilitating either virus production or virus-
induced tumorigenesis comes from two additional recent reports
(Marusawa et al, 2003; Zhu et al, 2003). Zhu et al showed that
human immunodeficiency virus type 1 (HIV-1) transcriptionally
upregulates survivin expression, that Vpr, an HIV-1 accessory
protein, is necessary and sufficient for this effect, and that survivin
may be actively involved in regulating cell viability during HIV-1
infection (Zhu et al, 2003). This likely facilitates virus production
by increasing host cell viability. More interestingly, Marusawa et al
showed that survivin forms complexes with a cellular protein,
hepatitis B X-interacting protein (HBXIP), which was originally
recognised for its association with the X protein (HBX) of hepatitis
B virus (HBV). Survivin–HBXIP complexes, but neither survivin
nor HBXIP individually, bind procaspase-9, preventing its
recruitment to Apaf1, and thereby selectively suppressing apop-
tosis initiated through the mitochondria/cytochrome c pathway
(Marusawa et al, 2003). Moreover, viral HBX protein also interacts
with the surviving–HBXIP complex and suppresses caspase
activation only in the presence of survivin (Marusawa et al,
2003). These observations highlighted that survivin is critical for
HBV-induced apoptosis inhibition. Thus, this study provides
direct evidence that survivin is likely involved in HBV pathogen-
induced hepatocellular tumorigenesis.
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Lo Muzio et al (2003) showed that survivin is immunohistochemi-
cally present in 10 out of 30 cases (33%) of oral precancerous
lesions without malignant progression, but in 15 out of 16 cases
(94%) of oral precancerous lesions which evolved into full-blown
SCC, and that survivin positivity appears to be an early event and a
critical factor for tumor progression from precancerous lesion.
Zhang et al showed that the immunohistochemical reactivity of
survivin is 4.2% (four out of 96) in normal mammary, 5.4% (three
out of 56) in cystic hyperplasia mammary, 42.7% (five out of 12) in
atypical hyperplasia mammary, and 72.3% (86 out of 119) in breast
carcinoma, and that the positive rates in the last two groups are
statistically significant in comparison with the former two groups
(Zhang et al, 2004a). Kim et al (2002) reported that in 41 cervical
intraepithelial neoplasia (CIN) and SCC tissues, survivin expres-
sion is 66.7% in low-grade (CIN I), 87.5% in high-grade (CIN II
and III), and 100% in SCC, which is statistically significant. These
observations provide additional evidence for the involvement of
survivin expression in tumorigenesis.
However, the most interesting observation comes from a study
of the skin carcinogenesis using a survivin-transgenic (Tg) mouse
model (Allen et al, 2003). Early observation from Grossman et al
(1999)indicated that survivin is immunohistochemically expressed
in 17 of 21 (81%) of basal cell carcinomas of both nodular and
morpheaform subtypes, and in 24 of 26 (92%) of cutaneous SCC.
Survivin is also expressed in 19 premalignant lesions of Bowen’s
disease and hypertrophic actinic keratosis. This suggests that
survivin expression occurs early during keratinocyte transforma-
tion and may play a role in carcinogenesis. Paradoxically, Allen
et al (2003) used DMBA carcinogen and PMA carcinogenic
promoter to induce skin tumour formation in a Tg mouse model
in which survivin is specifically overexpressed in skin driven by
the keratin-14 gene promoter. These authors found that tumour
formation was less frequent (31 vs 43%) and significantly delayed
in Tg mice in comparison with non-Tg littermates. However,
papilloma regression was not observed in Tg mice, whereas 20% of
papillomas regressed in non-Tgs. One SCC was generated in Tg
mice, whereas none were seen in non-Tgs. In another set of
experiments, Tg mice with p53þ/  background were used. Again,
DMBA/PMA-induced tumour formation was less (71 vs 89%) and
significantly delayed in Tg p53þ/  animals in comparison with
p53þ/  non-Tgs. However, papilloma regression was also not
observed in Tg p53þ/  mice, whereas 10% of papillomas
regressed in p53þ/  non-Tgs. The rate of papilloma progression
to SCC was 21% in Tg p53þ/  mice in comparison with 12% in
p53þ/  non-Tgs (Allen et al, 2003). Together, these authors
reported interesting results. The question is how to explain the
negative effect of survivin on skin carcinogenesis and the positive
effect on tumour progression. A recent report from the same
research group showed that apoptosis inhibition by Tg expression
of survivin enhances mutant clone creation and malignant
progression during UV-B treatments in the skin carcinogenesis
model, but inhibition of apoptosis by survivin in the neighbour
survivin-Tg-transgenic skin cells restricts mutant clone expansion
(tumour formation) (Zhang et al, 2004c). This may provide an
explanation for the paradoxical results above. Anyway, the model
will be significantly strengthened, if it could gain an insight into a
molecular basis to explain why apoptosis in the neighbour normal
cells is so important for the mutant clone to be expanded (tumour
growth) in skin.
Alternatively, in my personal view, the results from Allen et al
may also suggest that artificial overexpression of survivin in
normal tissues may show a different role from survivin expression
in abnormal precancerous and cancerous tissues. For example, the
artificial overexpression of survivin in normal mouse skin may
counter against the process of DMBA/PMA-induced carcinogen-
esis. However, through a selection process driven by DMBA/PMA
treatments, individual skin cells with additional genetic and/or
biochemical abnormalities will give survivin a different back-
ground for function. In the latter environment, survivin plays a
positive role in tumour growth/progression for promoting
papilloma regression and promoting conversion to SCC.
SURVIVIN VARIANTS IN TUMORIGENESIS
Human survivin gene has four dominant (1, 2, 3, and 4) and two
hidden (2B and 3B) exons. Alternative splicing of its pre-mRNA
produces four different mRNAs, which encode four distinct
proteins, survivin, survivin-2B, survivin-DEx3 (Mahotka et al,
1999), and survivin-3B (Badran et al, 2004). Survivin (142 aa) is
derived from exons 1–4; survivin-2B (167 aa) has an additional 23
aa derived from a 69-bp cryptic exon (2B) within intron 2, which is
spliced into survivin mRNA in frame between exons 2 and 3;
survivin-DEx3 (137 aa) is derived from exons 1, 2, and 4, a
frameshift read-through variant due to exon 3 escape; and the
recently reported survivin-3B (120 aa) consists of the N-terminal
113 aa of survivin (coded by exons 1, 2, and 3) plus seven new aa
sequences at C-terminal tail encoded by a DNA sequence (exon 3B)
from intron 3 of survivin. Currently, there is no strong evidence
suggesting that survivin splicing variants are involved in
tumorigenesis. However, Islam et al (2000) reported that the
expression of survivin-2B is predominant in some neuroblastoma
with a good prognosis, but it is expressed at low levels in most
malignant tissues. In renal cell carcinomas (RCC), while the
expression levels of survivin and survivin-DEx3 did not show a
decrease in late tumour stages in comparison with the early and
intermediate tumour stages in 57 clinical RCC samples, survivin-
2B expression was significantly decreased in late tumour stages
(Mahotka et al, 2002a), indicating a possible unfavourable role of
survivin-2B in cancer development. In gastric cancer, the
expression of survivin-DEx3, survivin-2B, and survivin (dominant
transcript) was found in cancer tissues, irrespective of their
histological type, grade, or stage (Krieg et al, 2002) (Meng et al,
2004). However, survivin-2B expression was significantly de-
creased in later tumour stage (IIIþIV) in comparison with early
stage (IþII) (Krieg et al, 2002; Meng et al, 2004), and inversely
correlated with tumour differentiation and invasion (Meng et al,
2004). Interestingly, although Krieg et al (2002) reported that the
expression of survivin and survivin-DEx3 remained unchanged in
different stages of cancer, Meng et al (2004) showed that the
expression level of survivin-DEx3 is inversely correlated with
apoptotic index. It was also reported that survivin-2B expression
was dominant in benign brain tumours in comparison with the
malignant ones (Yamada et al, 2003), and that survivin-DEx3
expression was prominent in comparison with survivin-2B
expression in survivin-expressing acute lymphocytic leukaemia
(ALL) and chronic lymphocytic leukaemia (CLL) patient bone
marrow samples (Nakagawa et al, 2004). Structurally, a novel
antiapoptotic protein encoded by open reading frame K7 of
Kaposi’s sarcoma-associated herpesvirus bears a resemblance to
survivin-DEx3 (Wang et al, 2002), further suggesting a possible
antiapoptotic role for survivin-DEx3. In addition, the different
subcellular localisation of survivin-DEx3 (in nucleus) and survi-
vin-2B (in cytoplasm) (Mahotka et al, 2002b) also suggests their
potential different roles. Collectively, these observations indicated
that survivin-DEx3 and survivin-2B may play an opposing role in
tumour progression and/or tumorigenesis.
Interestingly, in soft tissue sarcoma (STS), 36 of 56 STS (64%)
were survivin transcript-positive, and 15 of the 36 survivin-
positive samples were survivin-DEx3 transcript-positive, but
survivin-2B transcripts were undetectable (Kappler et al, 2001).
Similarly, among the 79 gastric tumour samples, the expression of
survivin, survivin-2B, and survivin-DEx3 was 79 (100%), 62
(78.5%), and 51 (64.6%), respectively (Meng et al, 2004).
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the expression of survivin was downregulated during retinoic acid-
induced apoptosis in CHP134 neuroblastoma cells, survivin-2B
expression was unchanged or slightly increased during apoptosis.
These observations suggest that the expression of these survivin
variants could be differentially regulated. Consistent with this
notion, recent studies from Zhu et al (2004) showed that one of the
mechanisms for p53 to induce apoptosis in ALL cells is through
differential modulation of survivin and its variants. Doxorubicin-
activated p53 upregulated survivin-2B but downregulated survivin
and survivin-DEx3. Therefore, from a cancer prevention and
therapeutics point of view, the idea that survivin-2B may act as a
natural antagonist against the function of survivin and/or survivin-
DEx3 may lead to novel approaches for cancer prevention and/or
therapeutics through differential modulation of the expression of
survivin and/or its variants.
SUMMARY REMARKS
The potential role of survivin in colorectal tumorigenesis appears
to be well defined. Many observations also indicate a role
of survivin in virus infection-induced carcinogenesis. In addition,
studies of normal and different stages of precancerous
and cancerous tissues in many other types of cancer also suggest
a role of survivin in tumorigenesis. However, the study of DMBA/
PMA-induced carcinogenesis in a mouse skin model (with
or without a p53þ/  background) that artificially overexpresses
survivin in skin using a skin-specific keratin-14 gene promoter,
paradoxically revealed that tumour formation was less frequent
and significantly delayed in survivin-Tg mice in comparison
with non-Tg littermates, although Tg mice promote papilloma
progression into SCC after tumours are initiated from DMBA/PMA
treatment. This interesting observation could be due to
the apoptosis inhibition by survivin in the neighbour normal
cells, which prevents mutant cell expansion (tumour growth), but
it may also suggest that the potential role of survivin in normal
skin is different from the role in precancerous and cancerous
tissues. Therefore, studies of the different role and functional
mechanism of survivin between normal and cancerous tissues will
help to answer the remaining questions. New research approaches
and/or model systems will be required to elucidate the distinct
mechanisms by which survivin functions and is regulated in cancer
vs normal cells, which will be essential for development of novel
and highly effective approaches for cancer prevention and
therapeutics. In addition, although data from several reports
suggest a potential role of survivin-2B in countering against the
function of survivin and/or survivin-DEx3 in tumour develop-
ments, much more needs to be done before deriving a definitive
conclusion.
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